ACADIA Financial Statements From 2010 to 2024

ACAD Stock  USD 17.05  0.03  0.18%   
ACADIA Pharmaceuticals financial statements provide useful quarterly and yearly information to potential ACADIA Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on ACADIA Pharmaceuticals financial statements helps investors assess ACADIA Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting ACADIA Pharmaceuticals' valuation are summarized below:
Gross Profit
145.5 M
Profit Margin
(0.08)
Market Capitalization
2.8 B
Enterprise Value Revenue
3.3623
Revenue
726.4 M
There are over one hundred nineteen available fundamental measures for ACADIA Pharmaceuticals, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of ACADIA Pharmaceuticals' latest performance against the performance from 2010 to 2024 to make sure the company is sustainable in the coming quarters. The current year's Market Cap is expected to grow to about 1.9 B. The current year's Enterprise Value is expected to grow to about 1.8 B

ACADIA Pharmaceuticals Total Revenue

762.76 Million

Check ACADIA Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ACADIA main balance sheet or income statement drivers, such as Interest Expense of 8 M, Selling General Administrative of 412.7 M or Total Revenue of 762.8 M, as well as many exotic indicators such as Price To Sales Ratio of 6.71, Dividend Yield of 0.0 or PTB Ratio of 12.47. ACADIA financial statements analysis is a perfect complement when working with ACADIA Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement ACADIA Pharmaceuticals' financial leverage analysis and stock options assessment as well as various ACADIA Pharmaceuticals Technical models . Check out the analysis of ACADIA Pharmaceuticals Correlation against competitors.
For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.

ACADIA Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets786.4 M749 M452.4 M
Slightly volatile
Short and Long Term Debt Total60.1 M57.2 M22.4 M
Slightly volatile
Common Stock Shares Outstanding172 M163.8 M114.6 M
Slightly volatile
Liabilities And Stockholders Equity786.4 M749 M452.4 M
Slightly volatile
Non Current Liabilities Total66.1 M62.9 M22.7 M
Slightly volatile
Total Liabilities333.1 M317.2 M101.6 M
Slightly volatile
Other Current Liabilities237 M225.7 M65.8 M
Slightly volatile
Total Current Liabilities267 M254.3 M75.9 M
Slightly volatile
Property Plant And Equipment Net59.3 M56.5 M21.9 M
Slightly volatile
Current Deferred Revenue1.3 M1.4 M1.4 M
Slightly volatile
Accounts Payable18.4 M17.5 M6.4 M
Slightly volatile
Cash198.1 M188.7 M118.5 M
Slightly volatile
Non Current Assets Total139.5 M132.8 M37.9 M
Slightly volatile
Non Currrent Assets Other2.6 M5.1 M3.3 M
Slightly volatile
Cash And Short Term Investments269.3 M438.9 M346.3 M
Slightly volatile
Common Stock Total Equity19.3 K18.4 K12 K
Slightly volatile
Short Term Investments185.1 M250.2 M235.4 M
Slightly volatile
Other Current Assets41 M39.1 M14.3 M
Slightly volatile
Property Plant And Equipment Gross69.3 M66 M23.2 M
Slightly volatile
Total Current Assets646.9 M616.1 M413.3 M
Slightly volatile
Short Term Debt9.9 M9.4 M4.8 M
Slightly volatile
Common Stock19.3 K18.4 K12 K
Slightly volatile
Property Plant Equipment74.4 M70.8 M20 M
Slightly volatile
Other Liabilities11 M10.4 M3.4 M
Slightly volatile
Net Tangible Assets403.1 M460.5 M352.3 M
Slightly volatile
Capital Surpluse1.6 B3.1 B1.6 B
Slightly volatile
Warrants14.1 M15.9 M17.3 M
Slightly volatile
Net Receivables107.5 M102.3 M32.4 M
Slightly volatile
Non Current Liabilities Other12.7 M15.1 MM
Slightly volatile
Net Invested Capital401.6 M431.8 M417.5 M
Slightly volatile
Net Working Capital383.3 M361.9 M400.6 M
Slightly volatile
Long Term InvestmentsM2.6 M1.7 M
Slightly volatile
Capital Stock17.1 K18.4 K15 K
Slightly volatile
Capital Lease Obligations50.5 M57.2 M24.5 M
Slightly volatile

ACADIA Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative412.7 M393.1 M209.8 M
Slightly volatile
Total Revenue762.8 M726.4 M243.3 M
Slightly volatile
Gross Profit714.7 M680.7 M230.1 M
Slightly volatile
Other Operating Expenses839.8 M799.8 M392.8 M
Slightly volatile
Research Development369.2 M351.6 M168.3 M
Slightly volatile
Total Operating Expenses791.8 M754.1 M379.5 M
Slightly volatile
Depreciation And Amortization5.8 M5.6 M2.2 M
Slightly volatile
Cost Of Revenue25.9 M45.7 M25.2 M
Very volatile
Tax Provision10.8 M10.2 M2.1 M
Slightly volatile
Interest Income18.1 M17.2 MM
Slightly volatile
Net Interest Income18.1 M17.2 M5.9 M
Slightly volatile
Reconciled Depreciation3.5 M5.6 MM
Slightly volatile
Selling And Marketing Expenses8.9 M9.4 M33.3 M
Slightly volatile

ACADIA Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow198.1 M188.7 M120.4 M
Slightly volatile
Begin Period Cash Flow76.1 M114.8 M99.9 M
Slightly volatile
Depreciation5.8 M5.6 M2.2 M
Slightly volatile
Total Cash From Financing Activities23.9 M25.1 M123.1 M
Very volatile
Stock Based Compensation63.1 M66.4 M204.1 M
Slightly volatile
Sale Purchase Of Stock19.8 M20.9 M122.8 M
Very volatile
Change To Netincome56.3 M71.2 M49.6 M
Slightly volatile
Issuance Of Capital Stock23.9 M25.1 M219.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.717.06075.8 K
Pretty Stable
Days Sales Outstanding48.8551.4261.7 K
Slightly volatile
Stock Based Compensation To Revenue0.08690.091487.6863
Slightly volatile
EV To Sales6.546.87985.6 K
Pretty Stable
Inventory Turnover2.541.27671.8247
Slightly volatile
Days Of Inventory On Hand154286251
Slightly volatile
Payables Turnover2.722.60681.9466
Slightly volatile
Sales General And Administrative To Revenue0.510.5411120
Pretty Stable
Research And Ddevelopement To Revenue0.460.484118
Pretty Stable
Cash Per Share4.082.6793.4119
Very volatile
Days Payables Outstanding226140255
Slightly volatile
Intangibles To Total Assets0.08260.07870.03
Slightly volatile
Current Ratio2.32.42339.6347
Slightly volatile
Receivables Turnover4.637.09764.1995
Slightly volatile
Graham Number4.474.710112.4656
Slightly volatile
Revenue Per Share4.664.43441.8355
Slightly volatile
Interest Debt Per Share0.330.34920.5175
Slightly volatile
Debt To Assets0.08420.07640.0461
Pretty Stable
Operating Cycle277337351
Slightly volatile
Days Of Payables Outstanding226140255
Slightly volatile
Ebt Per Ebit1.060.69550.9702
Slightly volatile
Quick Ratio2.022.12869.389
Slightly volatile
Net Income Per E B T0.821.20081.0043
Very volatile
Cash Ratio0.70.7422.5897
Slightly volatile
Days Of Inventory Outstanding154286251
Slightly volatile
Days Of Sales Outstanding48.8551.4261.7 K
Slightly volatile
Fixed Asset Turnover15.9312.864822.3019
Pretty Stable
Debt Ratio0.08420.07640.0461
Pretty Stable
Price Sales Ratio6.717.06075.8 K
Pretty Stable
Asset Turnover1.020.96990.3714
Slightly volatile
Gross Profit Margin0.740.9370.8365
Slightly volatile

ACADIA Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.9 B1.8 B1.7 B
Slightly volatile
Enterprise Value1.8 B1.7 B1.6 B
Slightly volatile

ACADIA Fundamental Market Drivers

Forward Price Earnings26.3852
Cash And Short Term Investments438.9 M

ACADIA Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About ACADIA Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include ACADIA Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. ACADIA Pharmaceuticals investors use historical funamental indicators, such as ACADIA Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although ACADIA Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in ACADIA Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ACADIA Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ACADIA Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ACADIA Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.4 M1.3 M
Total Revenue726.4 M762.8 M
Cost Of Revenue45.7 M25.9 M
Stock Based Compensation To Revenue 0.09  0.09 
Sales General And Administrative To Revenue 0.54  0.51 
Research And Ddevelopement To Revenue 0.48  0.46 
Capex To Revenue(0.06)(0.07)
Revenue Per Share 4.43  4.66 
Ebit Per Revenue(0.10)(0.11)

ACADIA Pharmaceuticals Investors Sentiment

The influence of ACADIA Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in ACADIA. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to ACADIA Pharmaceuticals' public news can be used to forecast risks associated with an investment in ACADIA. The trend in average sentiment can be used to explain how an investor holding ACADIA can time the market purely based on public headlines and social activities around ACADIA Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
ACADIA Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for ACADIA Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average ACADIA Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on ACADIA Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ACADIA Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ACADIA Pharmaceuticals' short interest history, or implied volatility extrapolated from ACADIA Pharmaceuticals options trading.

Pair Trading with ACADIA Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ACADIA Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ACADIA Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with ACADIA Stock

  0.73EGRX Eagle Pharmaceuticals Earnings Call This WeekPairCorr
  0.66JNJ Johnson Johnson Financial Report 18th of July 2024 PairCorr

Moving against ACADIA Stock

  0.79SNDL SNDL Inc Earnings Call This WeekPairCorr
  0.74CGC Canopy Growth Corp Financial Report 27th of June 2024 PairCorr
  0.72QLI Qilian InternationalPairCorr
  0.7IMCC Im Cannabis Corp Earnings Call This WeekPairCorr
  0.52PAHC Phibro Animal Health Earnings Call This WeekPairCorr
The ability to find closely correlated positions to ACADIA Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ACADIA Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ACADIA Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ACADIA Pharmaceuticals to buy it.
The correlation of ACADIA Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ACADIA Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ACADIA Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ACADIA Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:
Check out the analysis of ACADIA Pharmaceuticals Correlation against competitors.
For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.
Note that the ACADIA Pharmaceuticals information on this page should be used as a complementary analysis to other ACADIA Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Complementary Tools for ACADIA Stock analysis

When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Is ACADIA Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.37)
Revenue Per Share
4.434
Quarterly Revenue Growth
0.693
Return On Assets
(0.07)
Return On Equity
(0.15)
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.